Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Coronaviruses
  4. Fast Track Articles
  5. Fast Track Article
image of Emerging Threat: A Review on Mucormycosis as a Serious Health Challenge During the Pandemic

Abstract

During the COVID-19 pandemic, many critically ill patients undergoing intensive care or ventilation developed a fungal infection known as . This infection is primarily caused by ubiquitous fungi in the environment, such as species like , and , among others. Symptoms range from mild, such as fever and nasal congestion, to more severe manifestations, like gastrointestinal bleeding and dark lesions in moist body areas such as the nose and eyes. can be fatal if not promptly treated with appropriate combination therapy, and in severe cases, surgical removal of infected tissue may be necessary. This review explores the historical background, epidemiology, and treatment strategies for . It also discusses its prevalence among COVID-19 patients, underlying causes, and management protocols.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/covid/10.2174/0126667975341766241230072808
2025-01-06
2025-03-01

  • From This Site

    /content/journals/covid/10.2174/0126667975341766241230072808
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Ha T.S. Park C.M. Yang J.H. Cho Y.H. Chung C.R. Jeon K. Suh G.Y. Disseminated gastrointestinal mucormycosis in immunocompromised disease. Korean J. Crit. Care Med. 2015 30 4 323 328 10.4266/kjccm.2015.30.4.323
    [Google Scholar]
  2. Rodríguez-Gutiérrez G. Carrillo-Casas E.M. Arenas R. García-Méndez J.O. Toussaint S. Moreno-Morales M.E. Schcolnik-Cabrera A.A. Xicohtencatl-Cortes J. Hernández-Castro R. Mucormycosis in a non-hodgkin lymphoma patient caused by Syncephalastrum racemosum: case report and review of literature. Mycopathologia 2015 180 1-2 89 93 10.1007/s11046‑015‑9878‑1 25736172
    [Google Scholar]
  3. Dogra S. Arora A. Aggarwal A. Passi G. Sharma A. Singh G. Barnwal R.P. Mucormycosis amid COVID-19 crisis: pathogenesis, diagnosis, and novel treatment strategies to combat the spread. Front. Microbiol. 2022 12 794176 10.3389/fmicb.2021.794176 35058909
    [Google Scholar]
  4. Bavikar P. Mehta V. Rhino-orbital-cerebral mucormycosis: a fatal complication of uncontrolled diabetes mellitus. Cureus 2017 9 11 e1841 10.7759/cureus.1841 29348987
    [Google Scholar]
  5. Al Hassan F. Aljahli M. Molani F. Almomen A. Rhino-orbito-cerebral mucormycosis in patients with uncontrolled diabetes: A case series. Int. J. Surg. Case Rep. 2020 73 324 327 10.1016/j.ijscr.2020.07.011 32738774
    [Google Scholar]
  6. Walsh T.J. Hospenthal D.R. Petraitis V. Kontoyiannis D.P. Necrotizing mucormycosis of wounds following combat injuries, natural disasters, burns, and other trauma. J. Fungi 2019 5 3 57 10.3390/jof5030057 31277364
    [Google Scholar]
  7. Duarte-Rojo A. Allampati S. Thacker L.R. Flud C.R. Patidar K.R. White M.B. Klair J.S. Heuman D.M. Wade J.B. Gavis E.A. Bajaj J.S. Diagnosis of covert hepatic encephalopathy: a multi-center study testing the utility of single versus combined testing. Metab. Brain Dis. 2019 34 1 289 295 10.1007/s11011‑018‑0350‑z 30506333
    [Google Scholar]
  8. Xie J. Wu W. Li S. Hu Y. Hu M. Li J. Yang Y. Huang T. Zheng K. Wang Y. Kang H. Huang Y. Jiang L. Zhang W. Zhong M. Sang L. Zheng X. Pan C. Zheng R. Li X. Tong Z. Qiu H. Du B. Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study. Intensive Care Med. 2020 46 10 1863 1872 10.1007/s00134‑020‑06211‑2 32816098
    [Google Scholar]
  9. Berdai MA Labib S Harandou M Rhinocerebral mucormycosis complicating ketoacidosis diabetes. Presse Med. 2015 45 1 145 146
    [Google Scholar]
  10. Mora-Martínez A. Murcia L. Rodríguez-Lozano F.J. Oral Manifestations of Mucormycosis: A Systematic Review. J. Fungi 2023 9 9 935 10.3390/jof9090935 37755045
    [Google Scholar]
  11. Nilesh K. Vande A.V. Mucormycosis of maxilla following tooth extraction in immunocompetent patients: Reports and review. J. Clin. Exp. Dent. 2018 10 3 0 10.4317/jced.53655 29721234
    [Google Scholar]
  12. Reid G. Lynch J.P. III Fishbein M.C. Clark N.M. 2020
  13. Brunet K. Rammaert B. Mucormycosis treatment: Recommendations, latest advances, and perspectives. J. Mycol. Med. 2020 30 3 101007 10.1016/j.mycmed.2020.101007 32718789
    [Google Scholar]
  14. Sipsas N.V. Gamaletsou M.N. Anastasopoulou A. Kontoyiannis D.P. Therapy of Mucormycosis. J. Fungi 2018 4 3 90 10.3390/jof4030090 30065232
    [Google Scholar]
  15. Steinbrink J.M. Miceli M.H. Mucormycosis. Infectious Disease Clinics. 2021 35 2 435 452 34016285
    [Google Scholar]
  16. Kidd S.E. Chen S.C.A. Meyer W. Halliday C.L. A new age in molecular diagnostics for invasive fungal disease: are we ready? Front. Microbiol. 2020 10 2903 10.3389/fmicb.2019.02903 31993022
    [Google Scholar]
  17. Sedik S Wolfgruber S Hoenigl M Kriegl L Diagnosing fungal infections in clinical practice: A narrative review Expert Rev Anti Infect Ther. 2024 22 11 935 949 10.1080/14787210.2024.2403017
    [Google Scholar]
  18. Riley T.T. Muzny C.A. Swiatlo E. Legendre D.P. Breaking the Mold. Ann. Pharmacother. 2016 50 9 747 757 10.1177/1060028016655425 27307416
    [Google Scholar]
  19. Skiada A. Lass-Floerl C. Klimko N. Ibrahim A. Roilides E. Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med. Mycol. 2018 56 Suppl. 1 S93 S101 10.1093/mmy/myx101 29538730
    [Google Scholar]
  20. Chavda V.P. Apostolopoulos V. Mucormycosis – An opportunistic infection in the aged immunocompromised individual: A reason for concern in COVID-19. Maturitas 2021 154 58 61 10.1016/j.maturitas.2021.07.009 34364730
    [Google Scholar]
  21. Song G. Liang G. Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 2020 185 4 599 606 10.1007/s11046‑020‑00462‑9 32737747
    [Google Scholar]
  22. Mina S. Yaakoub H. Annweiler C. Dubée V. Papon N. COVID-19 and Fungal infections: a double debacle. Microbes Infect. 2022 24 8 105039 10.1016/j.micinf.2022.105039 36030024
    [Google Scholar]
  23. Naveen K.V. Saravanakumar K. Sathiyaseelan A. MubarakAli D. Wang M-H. MubarakAli D, Wang MH. Human fungal infection, immune response, and clinical challenge—a perspective during COVID-19 pandemic. Appl. Biochem. Biotechnol. 2022 194 9 4244 4257 10.1007/s12010‑022‑03979‑5 35648275
    [Google Scholar]
  24. Nazari T. Sadeghi F. Izadi A. Sameni S. Mahmoudi S. COVID-19-associated fungal infections in Iran: A systematic review. PLoS One 2022 17 7 e0271333 10.1371/journal.pone.0271333 35816494
    [Google Scholar]
  25. Liu D. Advances in nanomaterial-based targeted drug delivery systems. Front Bioeng Biotechnol 2023 11 1177151 10.1201/b22030‑47
    [Google Scholar]
  26. Pai V. Sansi R. Kharche R. Bandili S.C. Pai B. Rhino-orbito-cerebral mucormycosis: pictorial review. Insights Imaging 2021 12 1 167 10.1186/s13244‑021‑01109‑z 34767092
    [Google Scholar]
  27. Walther G. Wagner L. Kurzai O. Updates on the taxonomy of Mucorales with an emphasis on clinically important taxa. J. Fungi 2019 5 4 106 10.3390/jof5040106 31739583
    [Google Scholar]
  28. Jeong W. Keighley C. Wolfe R. Lee W.L. Slavin M.A. Kong D.C.M. Chen S.C.A. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin. Microbiol. Infect. 2019 25 1 26 34 10.1016/j.cmi.2018.07.011 30036666
    [Google Scholar]
  29. Walther G. Wagner L. Kurzai O. Outbreaks of Mucorales and the species involved. Mycopathologia 2020 185 5 765 781 31734800
    [Google Scholar]
  30. Pan J. Tsui C. Li M. Xiao K. de Hoog G.S. Verweij P.E. Cao Y. Lu H. Jiang Y. First case of rhinocerebral mucormycosis caused by Lichtheimia ornata, with a review of Lichtheimia infections. Mycopathologia 2020 185 3 555 567 10.1007/s11046‑020‑00451‑y 32388712
    [Google Scholar]
  31. Kottarathil M. Thayanidhi P. P S. Jyoti Kindo A. Rise of mucormycosis during the COVID-19 pandemic and the challenges faced. Curr. Med. Mycol. 2023 9 1 44 55 37867589
    [Google Scholar]
  32. Sharma A. Goel A. Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiol. (Praha) 2022 67 3 363 387 10.1007/s12223‑021‑00934‑5 35220559
    [Google Scholar]
  33. Shivaji S. Jayasudha R. Prashanthi G.S. Arunasri K. Das T. Fungi of the human eye: Culture to mycobiome. Exp. Eye Res. 2022 217 108968 10.1016/j.exer.2022.108968 35120870
    [Google Scholar]
  34. Compain F. Aït-Ammar N. Botterel F. Gibault L. Le Pimpec Barthes F. Dannaoui E. Fatal pulmonary mucormycosis due to Rhizopus homothallicus. Mycopathologia 2017 182 9-10 907 913 10.1007/s11046‑017‑0151‑7 28580534
    [Google Scholar]
  35. Zaman K. Rudramurthy S.M. Das A. Panda N. Honnavar P. Kaur H. Chakrabarti A. Molecular diagnosis of rhino-orbito-cerebral mucormycosis from fresh tissue samples. J. Med. Microbiol. 2017 66 8 1124 1129 10.1099/jmm.0.000560 28792370
    [Google Scholar]
  36. Prakash H. Chakrabarti A. Global epidemiology of mucormycosis. J. Fungi 2019 5 1 26 10.3390/jof5010026 30901907
    [Google Scholar]
  37. Chander J. Singla N. Kaur M. Punia R.S. Attri A. Alastruey-Izquierdo A. Cano-Lira J.F. Stchigel A.M. Guarro J. Saksenaea erythrospora, an emerging mucoralean fungus causing severe necrotizing skin and soft tissue infections – a study from a tertiary care hospital in north India. Infect. Dis. (Lond.) 2017 49 3 170 177 10.1080/23744235.2016.1239027 27701965
    [Google Scholar]
  38. Patel A. Kaur H. Xess I. Michael J.S. Savio J. Rudramurthy S. Singh R. Shastri P. Umabala P. Sardana R. Kindo A. Capoor M.R. Mohan S. Muthu V. Agarwal R. Chakrabarti A. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin. Microbiol. Infect. 2020 26 7 944.e9 944.e15 10.1016/j.cmi.2019.11.021 31811914
    [Google Scholar]
  39. Corzo-León D.E. Chora-Hernández L.D. Rodríguez-Zulueta A.P. Walsh T.J. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases. Med. Mycol. 2018 56 1 29 43 10.1093/mmy/myx017 28431008
    [Google Scholar]
  40. Kontoyiannis D.P. Azie N. Franks B. Horn D.L. Prospective antifungal therapy ( PATH ) alliance ® : focus on mucormycosis. Mycoses 2014 57 4 240 246 10.1111/myc.12149 24147728
    [Google Scholar]
  41. Sephton-Clark PC Voelz K Spore germination of pathogenic filamentous fungi. Advances in Applied Microbiology 2018 102 117 157 10.1016/bs.aambs.2017.10.002
    [Google Scholar]
  42. Sun H. Saeedi P. Karuranga S. Pinkepank M. Ogurtsova K. Duncan B.B. Stein C. Basit A. Chan J.C.N. Mbanya J.C. Pavkov M.E. Ramachandaran A. Wild S.H. James S. Herman W.H. Zhang P. Bommer C. Kuo S. Boyko E.J. Magliano D.J. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022 183 109119 10.1016/j.diabres.2021.109119 34879977
    [Google Scholar]
  43. Chegini Z. Didehdar M. Khoshbayan A. Rajaeih S. Salehi M. Shariati A. Epidemiology, clinical features, diagnosis and treatment of cerebral mucormycosis in diabetic patients: A systematic review of case reports and case series. Mycoses 2020 63 12 1264 1282 10.1111/myc.13187 32965744
    [Google Scholar]
  44. Dolatabadi S. Ahmadi B. Rezaei-Matehkolaei A. Zarrinfar H. Skiada A. Mirhendi H. Nashibi R. Niknejad F. Nazeri M. Rafiei A. Gharaghani M. Erami M. Taghipour S. Piri F. Makimura K. Mucormycosis in Iran: A six-year retrospective experience. J. Mycol. Med. 2018 28 2 269 273 10.1016/j.mycmed.2018.02.014 29545123
    [Google Scholar]
  45. Khanam A. Hithamani G. Naveen J. Pradeep S.R. Barman S. Srinivasan K. Management of invasive infections in diabetes mellitus: A comprehensive review. Biologics 2023 3 1 40 71 10.3390/biologics3010004
    [Google Scholar]
  46. Kemparaju S. Mucormycosis Review in Post Covid Patients. Med. Mycol. Open Access 2022 8 3 29
    [Google Scholar]
  47. Gosavi JA Prabhu TT Sawant AA C-109 nanotechnology: Multifunctional smart nanoparticles measure previously invisible diagnostic analytes. JAIDS 2014 67 53
    [Google Scholar]
  48. Morales-Franco B. Nava-Villalba M. Medina-Guerrero E.O. Sánchez-Nuño Y.A. Davila-Villa P. Anaya-Ambriz E.J. Charles-Niño C.L. Host-pathogen molecular factors contribute to the pathogenesis of Rhizopus spp. in diabetes mellitus. Curr. Trop. Med. Rep. 2021 8 1 6 17 10.1007/s40475‑020‑00222‑1 33500877
    [Google Scholar]
  49. Tissot F Agrawal S Pagano L Petrikkos G Groll AH Skiada A Lass-Flörl C Calandra T Viscoli C Herbrecht R Nanotech approaches to drug delivery and imaging. Drug Discovery Today 2003 8 24 1112 1120
    [Google Scholar]
  50. Pilmis B. Alanio A. Lortholary O. Lanternier F. Recent advances in the understanding and management of mucormycosis. F1000 Res. 2018 7 1429 10.12688/f1000research.15081.1 30271573
    [Google Scholar]
  51. Kontoyiannis D.P. Yang H. Song J. Kelkar S.S. Yang X. Azie N. Harrington R. Fan A. Lee E. Spalding J.R. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect. Dis. 2016 16 1 730 10.1186/s12879‑016‑2023‑z 27905900
    [Google Scholar]
  52. Gebremariam T. Lin L. Liu M. Kontoyiannis D.P. French S. Edwards J.E. Jr Filler S.G. Ibrahim A.S. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J. Clin. Invest. 2016 126 6 2280 2294 10.1172/JCI82744 27159390
    [Google Scholar]
  53. Keller F. Antoni H. Minarcikova P. Hrdy O. Gal R. Mucormycosis in a Severe Trauma Patient Treated with a Combination of Systemic Posaconazole and Topical Amphotericin B—Case Report. Antibiotics 2023 12 10 1489 10.3390/antibiotics12101489 37887190
    [Google Scholar]
  54. Stemler J. Mellinghoff S.C. Khodamoradi Y. Sprute R. Classen A.Y. Zapke S.E. Hoenigl M. Krause R. Schmidt-Hieber M. Heinz W.J. Klein M. Koehler P. Liss B. Koldehoff M. Buhl C. Penack O. Maschmeyer G. Schalk E. Lass-Flörl C. Karthaus M. Ruhnke M. Cornely O.A. Teschner D. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). J. Antimicrob. Chemother. 2023 78 8 1813 1826 10.1093/jac/dkad143 37311136
    [Google Scholar]
  55. Chowdhary A. Singh P.K. Kathuria S. Hagen F. Meis J.F. Comparison of the EUCAST and CLSI broth microdilution methods for testing isavuconazole, posaconazole, and amphotericin B against molecularly identified Mucorales species. Antimicrob. Agents Chemother. 2015 59 12 7882 7887 10.1128/AAC.02107‑15 26438489
    [Google Scholar]
  56. Johnson K Parham KO Colon-targeted oral drug delivery systems: Design trends and approaches. AAPS PharmSciTech 2015 16 4 731 741 Nasal and paranasal sinus infections. 2015
    [Google Scholar]
  57. Manogaran R Mathialagan A Keshri A Bhuskute G Kumar A Srivastava A Marak RS Behari S Strategic approaches for colon targeted drug delivery: An overview of recent advancements. Pharmaceutics 2020 12 1 68 10.1007/978‑981‑16‑9729‑6_12
    [Google Scholar]
  58. Chikley A. Ben-Ami R. Kontoyiannis D.P. Mucormycosis of the central nervous system. J. Fungi 2019 5 3 59 10.3390/jof5030059 31288475
    [Google Scholar]
  59. Pfaller M.A. Rhomberg P.R. Wiederhold N.P. Gibas C. Sanders C. Fan H. Mele J. Kovanda L.L. Castanheira M. In vitro activity of isavuconazole against opportunistic fungal pathogens from two mycology reference laboratories. Antimicrob. Agents Chemother. 2018 62 10 e01230-18 10.1128/AAC.01230‑18 30061288
    [Google Scholar]
  60. Lamoth F. Damonti L. Alexander B.D. Role of antifungal susceptibility testing in non-Aspergillus invasive mold infections. J. Clin. Microbiol. 2016 54 6 1638 1640 10.1128/JCM.00318‑16 27008871
    [Google Scholar]
  61. Chen L. Krekels E.H.J. Verweij P.E. Buil J.B. Knibbe C.A.J. Brüggemann R.J.M. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs 2020 80 7 671 695 10.1007/s40265‑020‑01306‑y 32323222
    [Google Scholar]
  62. Gebremariam T. Liu M. Luo G. Bruno V. Phan Q.T. Waring A.J. Edwards J.E. Jr Filler S.G. Yeaman M.R. Ibrahim A.S. CotH3 mediates fungal invasion of host cells during mucormycosis. J. Clin. Invest. 2014 124 1 237 250 10.1172/JCI71349 24355926
    [Google Scholar]
  63. Peng M. Meng H. Sun Y. Xiao Y. Zhang H. Lv K. Cai B. Clinical features of pulmonary mucormycosis in patients with different immune status. J. Thorac. Dis. 2019 11 12 5042 5052 10.21037/jtd.2019.12.53 32030220
    [Google Scholar]
  64. Idol R.A. Bhattacharya S. Huang G. Song Z. Huttenlocher A. Keller N.P. Dinauer M.C. Neutrophil and macrophage NADPH oxidase 2 differentially control responses to inflammation and to Aspergillus fumigatus in mice. J. Immunol. 2022 209 10 1960 1972 10.4049/jimmunol.2200543 36426951
    [Google Scholar]
  65. Roilides E. Antachopoulos C. Simitsopoulou M. Pathogenesis and host defence against Mucorales: the role of cytokines and interaction with antifungal drugs. Mycoses 2014 57 s3 Suppl. 3 40 47 10.1111/myc.12236 25175306
    [Google Scholar]
  66. Gaeddert A. Healing digestive disorders: natural treatments for gastrointestinal conditions. People's Medical Publishing House 2018
    [Google Scholar]
  67. Vasudevan B. Hazra N. Shijith K.P. Neema S. Vendhan S. Mucormycosis. Indian J. Dermatol. 2021 66 4 393 400 10.4103/ijd.ijd_477_21 34759398
    [Google Scholar]
  68. Challa S. Mucormycosis: Pathogenesis and Pathology. Curr. Fungal Infect. Rep. 2019 13 1 11 20 10.1007/s12281‑019‑0337‑1
    [Google Scholar]
  69. Trief D. Gray S.T. Jakobiec F.A. Durand M.L. Fay A. Freitag S.K. Lee N.G. Lefebvre D.R. Holbrook E. Bleier B. Sadow P. Rashid A. Chhabra N. Yoon M.K. Invasive fungal disease of the sinus and orbit: a comparison between mucormycosis and Aspergillus. Br. J. Ophthalmol. 2016 100 2 184 188 10.1136/bjophthalmol‑2015‑306945 26112869
    [Google Scholar]
  70. Mohammadi R Nazeri M Sayedayn SM Ehteram H A successful treatment of rhinocerebral mucormycosis due to Rhizopus oryzae. J Res Med Sci. 2014 19 1 72 74
    [Google Scholar]
  71. Bell V Guina J Fernandes TH African fermented foods and beverages. Potential impact on health. 2023 293 322
    [Google Scholar]
  72. Otto W.R. Pahud B.A. Yin D.E. Pediatric mucormycosis: a 10-year systematic review of reported cases and review of the literature. J. Pediatric Infect. Dis. Soc. 2019 8 4 342 350 10.1093/jpids/piz007 31181136
    [Google Scholar]
  73. Liu M. Liu S.W. Wang L.J. Bai Y.M. Zeng X.Y. Guo H.B. Liu Y.N. Jiang Y.Y. Dong W.L. He G.X. Zhou M.G. Yu S.C. Burden of diabetes, hyperglycaemia in China from to 2016: Findings from the 1990 to 2016, global burden of disease study. Diabetes Metab. 2019 45 3 286 293 10.1016/j.diabet.2018.08.008 30196138
    [Google Scholar]
  74. Basu S. Vellakkal S. Agrawal S. Stuckler D. Popkin B. Ebrahim S. Averting obesity and type 2 diabetes in India through sugar-sweetened beverage taxation: an economic-epidemiologic modeling study. PLoS Med. 2014 11 1 e1001582 10.1371/journal.pmed.1001582 24409102
    [Google Scholar]
  75. Akhila Das S. A Study to Assess The Prevalence of Pre-diabetic among Adults Residing in Selected Village at Unnamalaikadai, Kanyakumari District, Tamilnadu. International Journal of Midwifery Nursing. 2021 4 2 1 6p
    [Google Scholar]
  76. Kumar J Roy V Mishra MC Prevalence of type 2 diabetes mellitus in adult population of durg district of Chhattisgarh, India: A hospital based study. Afr J Biomed Res. 2021 12 10
    [Google Scholar]
  77. Kumar M. Shahnawaz K. Association of diabetes mellitus with stroke: a hospital-based case-control study. J. Evol. Med. Dent. Sci. 2016 5 55 3733 3736 10.14260/jemds/2016/856
    [Google Scholar]
  78. Panchal M. Jivarajani H. Prevalence and clinical profile of various complications in type-2 Diabetes Mellitus patients. Natl. J. Integr. Res. Med. 2017 8 6
    [Google Scholar]
  79. Reddy S.S. Rakesh N. Chauhan P. Sharma S. Rhinocerebral mucormycosis among diabetic patients: an emerging trend. Mycopathologia 2015 180 5-6 389 396 10.1007/s11046‑015‑9934‑x 26349570
    [Google Scholar]
  80. Kim Y.I. Kang H.C. Lee H.S. Choi J.S. Seo K.H. Kim Y.H. Na J. Invasive pulmonary mucormycosis with concomitant lung cancer presented with massive hemoptysis by huge pseudoaneurysm of pulmonary artery. Ann. Thorac. Surg. 2014 98 5 1832 1835 10.1016/j.athoracsur.2013.12.051 25441799
    [Google Scholar]
  81. Muszewska A. Pawłowska J. Krzyściak P. Biology, systematics, and clinical manifestations of Zygomycota infections. Eur. J. Clin. Microbiol. Infect. Dis. 2014 33 8 1273 1287 10.1007/s10096‑014‑2076‑0 24615580
    [Google Scholar]
  82. Vallabhaneni S. Mody R.K. Gastrointestinal mucormycosis in neonates: A review. Curr. Fungal Infect. Rep. 2015 9 4 269 274 10.1007/s12281‑015‑0239‑9
    [Google Scholar]
  83. Francis J.R. Villanueva P. Bryant P. Blyth C.C. Mucormycosis in children: review and recommendations for management. J. Pediatric Infect. Dis. Soc. 2018 7 2 159 164 10.1093/jpids/pix107 29294067
    [Google Scholar]
  84. Singh A.K. Singh R. Joshi S.R. Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab. Syndr. 2021 15 4 102146 10.1016/j.dsx.2021.05.019 34192610
    [Google Scholar]
  85. Hoenigl M. Enoch D.A. Wichmann D. Wyncoll D. Cortegiani A. Exploring European Consensus About the Remaining Treatment Challenges and Subsequent Opportunities to Improve the Management of Invasive Fungal Infection (IFI) in the Intensive Care Unit. Mycopathologia 2024 189 3 41 10.1007/s11046‑024‑00852‑3 38704761
    [Google Scholar]
  86. Rausch C.R. DiPippo A.J. Bose P. Kontoyiannis D.P. Breakthrough fungal infections in patients with leukemia receiving isavuconazole. Clin. Infect. Dis. 2018 67 10 1610 1613 10.1093/cid/ciy406 29771293
    [Google Scholar]
  87. Pana Z.D. Seidel D. Skiada A. Groll A.H. Petrikkos G. Cornely O.A. Roilides E. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect. Dis. 2016 16 1 667 10.1186/s12879‑016‑2005‑1 27832748
    [Google Scholar]
  88. Bala K. Chander J. Handa U. Punia R.S. Attri A.K. A prospective study of mucormycosis in north India: Experience from a tertiary care hospital. Med. Mycol. 2015 53 3 248 257 10.1093/mmy/myu086 25587084
    [Google Scholar]
  89. Serris A. Danion F. Lanternier F. Disease entities in mucormycosis. J. Fungi 2019 5 1 23 10.3390/jof5010023 30875744
    [Google Scholar]
  90. Priya P. Rajendran T. Geni V.G. Geni V.G. Mucormycosis in a tertiary care center in South India: a 4-year experience. Indian J. Crit. Care Med. 2020 24 3 168 171 10.5005/jp‑journals‑10071‑23387 32435094
    [Google Scholar]
  91. Chander J. Kaur M. Singla N. Punia R. Singhal S. Attri A. Alastruey-Izquierdo A. Stchigel A. Cano-Lira J. Guarro J. Mucormycosis: battle with the deadly enemy over a five-year period in India. J. Fungi 2018 4 2 46 10.3390/jof4020046 29642408
    [Google Scholar]
  92. Cornely O.A. Alastruey-Izquierdo A. Arenz D. Chen S.C.A. Dannaoui E. Hochhegger B. Hoenigl M. Jensen H.E. Lagrou K. Lewis R.E. Mellinghoff S.C. Mer M. Pana Z.D. Seidel D. Sheppard D.C. Wahba R. Akova M. Alanio A. Al-Hatmi A.M.S. Arikan-Akdagli S. Badali H. Ben-Ami R. Bonifaz A. Bretagne S. Castagnola E. Chayakulkeeree M. Colombo A.L. Corzo-León D.E. Drgona L. Groll A.H. Guinea J. Heussel C.P. Ibrahim A.S. Kanj S.S. Klimko N. Lackner M. Lamoth F. Lanternier F. Lass-Floerl C. Lee D.G. Lehrnbecher T. Lmimouni B.E. Mares M. Maschmeyer G. Meis J.F. Meletiadis J. Morrissey C.O. Nucci M. Oladele R. Pagano L. Pasqualotto A. Patel A. Racil Z. Richardson M. Roilides E. Ruhnke M. Seyedmousavi S. Sidharthan N. Singh N. Sinko J. Skiada A. Slavin M. Soman R. Spellberg B. Steinbach W. Tan B.H. Ullmann A.J. Vehreschild J.J. Vehreschild M.J.G.T. Walsh T.J. White P.L. Wiederhold N.P. Zaoutis T. Chakrabarti A. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 2019 19 12 e405 e421 10.1016/S1473‑3099(19)30312‑3 31699664
    [Google Scholar]
  93. Kadiri S.K. Khobragade D.S. Roy S.P. Preclinical Appraisal of the Aphrodisiac Effects of Emblica officinalis Seed Extract on Stress-induced Sexual Behavior in Albino Rats. Curr. Drug Ther. 2024 19 5 594 603 10.2174/1574885518666230804113303
    [Google Scholar]
  94. Kadiri Kumar Sunil M. Suhas, Khobragade Shamrao Deepak, Kumar Vijay Merugumolu, Mudigubba Kumar Manoj, Bindigi Gowda Ramana, Current Perspectives and Innovative Approaches in Treating CysticFibrosis-Related Diabetes: Unveiling Mechanisms for Precision Medicine Current Drug Therapy 2024 19 240524230311 10.2174/0115748855304379240517043133
    [Google Scholar]
  95. Afroze S. Korlepara R. Rao G. Madala J. Mucormycosis in a diabetic patient: A case report with an insight into its pathophysiology. Contemp. Clin. Dent. 2017 8 4 662 666 10.4103/ccd.ccd_558_17 29326525
    [Google Scholar]
  96. Bonifaz A. Tirado-Sánchez A. Hernández-Medel M.L. Araiza J. Kassack J.J. del Angel-Arenas T. Moisés-Hernández J.F. Paredes-Farrera F. Gómez-Apo E. Treviño-Rangel R.J. González G.M. Mucormycosis at a tertiary‐care center in Mexico. A 35‐year retrospective study of 214 cases. Mycoses 2021 64 4 372 380 10.1111/myc.13222 33253454
    [Google Scholar]
  97. Gebremariam T. Alkhazraji S. Alqarihi A. Wiederhold N.P. Najvar L.K. Patterson T.F. Filler S.G. Ibrahim A.S. Evaluation of sex differences in murine diabetic ketoacidosis and neutropenic models of invasive mucormycosis. J. Fungi 2021 7 4 313 10.3390/jof7040313 33919611
    [Google Scholar]
  98. Muthu V. Agarwal R. Dhooria S. Sehgal I.S. Prasad K.T. Aggarwal A.N. Chakrabarti A. Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis. Clin. Microbiol. Infect. 2021 27 4 538 549 10.1016/j.cmi.2020.12.035 33418022
    [Google Scholar]
  99. Toniolo A. Cassani G. Puggioni A. Rossi A. Colombo A. Onodera T. Ferrannini E. The diabetes pandemic and associated infections: suggestions for clinical microbiology. Rev. Med. Microbiol. 2019 30 1 1 17 10.1097/MRM.0000000000000155 30662163
    [Google Scholar]
  100. Chow V. Khan S. Balogun A. Mitchell D. Mühlschlegel F.A. Invasive rhino-orbito-cerebral mucormycosis in a diabetic patient – the need for prompt treatment. Med. Mycol. Case Rep. 2015 8 5 9 10.1016/j.mmcr.2014.12.002 25750854
    [Google Scholar]
  101. Chaulk A.L. Do T.H. Supsupin E.P. Bhattacharjee M.B. Richani K. Adesina O.O.O. A unique radiologic case of optic nerve infarction in a patient with mucormycosis. J. Neuroophthalmol. 2021 41 3 e354 e356 10.1097/WNO.0000000000001179 33449489
    [Google Scholar]
  102. Dogra M. Bhutani G. Gupta V. Mucormycosis endophthalmitis in a silicone oil-filled eye of an immunocompetent patient. Ocul. Immunol. Inflamm. 2019 27 8 1293 1295 10.1080/09273948.2018.1518462 30192700
    [Google Scholar]
  103. Tucey T.M. Verma J. Harrison P.F. Snelgrove S.L. Lo T.L. Scherer A.K. Barugahare A.A. Powell D.R. Wheeler R.T. Hickey M.J. Beilharz T.H. Naderer T. Traven A. Glucose homeostasis is important for immune cell viability during Candida challenge and host survival of systemic fungal infection. Cell Metab. 2018 27 5 988 1006.e7 10.1016/j.cmet.2018.03.019 29719235
    [Google Scholar]
  104. Rai S. Misra D. Misra A. Jain A. Jain P. Dhawan A. Palatal mucormycosis masquerading as bacterial and fungal osteomyelitis: A rare case report. Contemp. Clin. Dent. 2018 9 2 309 313 10.4103/ccd.ccd_743_17 29875579
    [Google Scholar]
  105. Bonifaz A. Tirado-Sánchez A. Calderón L. Romero-Cabello R. Kassack J. Ponce R.M. Mena C. Stchigel A. Cano J. Guarro J. Mucormycosis in children: a study of 22 cases in a Mexican hospital. Mycoses 2014 57 s3 Suppl. 3 79 84 10.1111/myc.12233 25175081
    [Google Scholar]
  106. Sen M. Honavar S.G. Sharma N. Sachdev M.S. COVID-19 and Eye. Indian J. Ophthalmol. 2021 69 3 488 509 10.4103/ijo.IJO_297_21 33595463
    [Google Scholar]
  107. Garg D. Muthu V. Sehgal I.S. Ramachandran R. Kaur H. Bhalla A. Puri G.D. Chakrabarti A. Agarwal R. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 2021 186 2 289 298 10.1007/s11046‑021‑00528‑2 33544266
    [Google Scholar]
  108. Balushi A.A. Ajmi A.A. Sinani Q.A. Menon V. Berieki Z.A. Shezawi A.A. Azri S.A. Rashdi A.A. Jardani A.A. Baluki T.A. Ghaithi S.A. Reesi A.A. Al-Za’abi A.T. Al’ Balushi M.A. Maqbali T.A. COVID-19-associated mucormycosis: an opportunistic fungal infection. A case series and review. Int. J. Infect. Dis. 2022 121 203 210 10.1016/j.ijid.2022.05.005 35533833
    [Google Scholar]
  109. Selarka L. Sharma S. Saini D. Sharma S. Batra A. Waghmare V.T. Dileep P. Patel S. Shah M. Parikh T. Darji P. Patel A. Goswami G. Shah A. Shah S. Lathiya H. Shah M. Sharma P. Chopra S. Gupta A. Jain N. Khan E. Sharma V.K. Sharma A.K. Chan A.C.Y. Ong J.J.Y. Mucormycosis and COVID‐19: An epidemic within a pandemic in India. Mycoses 2021 64 10 1253 1260 10.1111/myc.13353 34255907
    [Google Scholar]
/content/journals/covid/10.2174/0126667975341766241230072808
Loading
Emerging Threat: A Review on Mucormycosis as a Serious Health Challenge During the Pandemic
Bentham Science Publishers ; https://doi.org/10.2174/0126667975341766241230072808
/content/journals/covid/10.2174/0126667975341766241230072808
/content/journals/covid/10.2174/0126667975341766241230072808
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: rhizopus ; mucor ; lichtheimia ; black fungus ; Mucormycosis ; infection ; rhizomucor
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test